Procter & Gamble Health Limited (NSE:PGHL)

Market Cap	104.14B +16.0%
Revenue (ttm)	14.08B +15.6%
Net Income	3.27B +30.1%
EPS	196.94 +30.3%
Shares Out	n/a
PE Ratio	31.85
Forward PE	29.05
Dividend	205.00 (3.26%)
Ex-Dividend Date	Aug 21, 2026

Volume	11,812
Open	6,210.00
Previous Close	6,207.00
Day's Range	6,205.00 - 6,333.00
52-Week Range	4,707.00 - 6,739.00
Beta	0.24
Analysts	Strong Buy
Price Target	7,535.00 (+19.85%)
Earnings Date	May 26, 2026

About Procter & Gamble Health

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble H...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 1,326
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PGHL

Financial Performance

In fiscal year 2026, Procter & Gamble Health's revenue was 14.08 billion, an increase of 15.59% compared to the previous year's 12.18 billion. Earnings were 3.27 billion, an increase of 30.14%.